While the world focuses on COVID-19, NGT’s Michael K. O’Brien and Philip Chu provide insight on the current state of the market for antimicrobial resistant (AMR) medicines. Read the article in Applied Clinical Trials Online. Please visit: https://www.appliedclinicaltrialsonline.com/view/market-failure-antimicrobial-resistant-medicines
